Skip to content
Sign in
Health · Africa

Ugandan researchers enroll first volunteers in Ebola vaccine trial

Reports place the experimental Ebola vaccine trial in the Democratic Republic of Congo, not Uganda. The available source material does not verify volunteer numbers, the virus strain or recruitment plans.

AI-assisted synthesis · Based on 8 independent reports from 9 outlets · Article text read from 1 of 8 reportsHow it's made

View timeline · 6 entries
9 outlets3 regionsLatest reporting 4 min read
Coverage: Center OnlyL 0 · C 7 · R 1 · 1 unrated
Updat3 graphic: Uganda
Updat3 graphic · Map data: Natural Earth Natural Earth (public domain)

What happened

Key facts

  • Ugandan scientists have begun a Phase One human clinical trial of the experimental vaccine candidate ChAdOx1 BDBV, targeting the Bundibugyo strain of Ebola (per zawya.com).
  • Headlines from Al Jazeera, The Straits Times, The Hindu, AFP, Le Monde, Winnipeg Sun, Bloomberg and MENAFN report that an Ebola vaccine trial has begun in the Democratic Republic of Congo.
  • The first five volunteers have enrolled in the Phase One trial (per zawya.com).
  • Principal investigator Dr Eugene Ruzagira said researchers plan to recruit about 110 healthy candidates aged 18 to 55 (per zawya.com).
  • Uganda declared its 2026 Ebola outbreak over on July 28 after 42 days without detecting further transmission (per zawya.com).

The brief

Ugandan scientists have started the first phase of human clinical testing for an experimental vaccine against the Bundibugyo strain of Ebola, enrolling five volunteers. The vaccine candidate is called ChAdOx1 BDBV. The East African, in an article carried by Zawya, identifies the research as a Phase One trial and says the initial participants have already joined it.

Principal investigator Dr Eugene Ruzagira said the researchers aim to recruit about 110 healthy candidates, all aged between 18 and 55. The account describes this as the planned size and age range for the trial; it does not give a completion date or further details about the study’s procedures.

The trial is focused on the Bundibugyo strain, which the article also identifies as the cause of Uganda’s 2026 Ebola outbreak. Uganda declared that outbreak over on July 28, after the required 42-day monitoring period passed without further detected transmission. The last confirmed patient was discharged on June 16.

The outbreak in Uganda recorded 20 confirmed cases and two deaths, according to the article. It says the outbreak’s patient zero had been imported from the Democratic Republic of Congo, where more than 8,500 cases have been reported so far.

Those figures provide the account’s regional context for a vaccine candidate aimed at the same strain, while the report does not connect the current trial to a specific outbreak-control decision.

Headlines from Al Jazeera, The Straits Times, The Hindu, AFP, Le Monde, Winnipeg Sun, Bloomberg and MENAFN also report that an Ebola vaccine trial has begun in the Democratic Republic of Congo.

Those headlines identify the trial’s location, while The East African’s text describes the researchers as Ugandan scientists and does not state that the trial is taking place in the Democratic Republic of Congo. The next stated step is recruitment: Ruzagira’s team plans to add participants toward its target of about 110 healthy candidates aged 18 to 55.

The reported enrollment of five marks the trial’s starting point, while the account gives no further results from the clinical testing.

Why it matters

  • The Phase One trial will assess whether the Bundibugyo-targeting vaccine is safe in people, an essential step before larger studies can test whether it prevents infection. It offers no immediate protection, but if later trials show it works, the vaccine could give health authorities a tool tailored to outbreaks of this Ebola strain and help protect people in affected communities and frontline workers.

What to watch next

  • In the coming days, check whether Uganda’s health ministry or the trial sponsors publish an official confirmation of the ChAdOx1 BDBV study, its location and the first enrollment.
  • Over the next few weeks, look for a trial-registry entry or protocol identifying the lead investigators, ethics approval, target enrollment and Bundibugyo strain.
  • Watch for clarification from Democratic Republic of Congo health authorities and the outlets reporting a trial there on whether their coverage refers to a separate study.
  • Monitor WHO and Uganda health-ministry updates for any change in Ebola surveillance or outbreak status that could affect plans for vaccine research.

How it's being covered

Coverage analysisShow details
9 source articles · 9 unique outlets · 4 distinct reports
Outlet political mix: Center Only· 7 Center · 1 Right · 1 unrated
Where the outlets are based: Unknown 33% · Asia 22% · Other 45%
Outlet political mix
Center Only
Left
Center
Right
0 outlets
7 outlets
1 outlet
The marker shows coverage balance: each unique outlet counts once. 1 unrated outlet is not included.
Geography
Where the outlets covering this story are based.
9 unique outletsDominant coverage: Asia
Coverage imbalance
  • Coverage is currently concentrated among Center-rated outlets (7 of 8 rated sources); comparatively few Left-rated outlets have published on the event.
How we measure coverage

2 sources are from a wire service (AP, Reuters, AFP or Bloomberg), whose reporting other outlets often republish.

How outlets' accounts compare

Updat3 does not yet have enough full reports to compare how outlets framed this story.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. Bundibugyo ebolavirus was identified during an outbreak in western Uganda in 2007.
    Background · from our historical context
  2. Researchers established Bundibugyo virus as a distinct Ebola species.
    Background · compiled and fact-checked by Updat3
  3. The World Health Organization declared the West African Ebola epidemic a public health emergency of international concern.
    Background · compiled and fact-checked by Updat3
  4. Uganda declared an outbreak of Sudan ebolavirus after confirming a case in Mubende district.
    Background · compiled and fact-checked by Updat3
  5. A vaccine study launched during that outbreak tested candidates directed at the Sudan species; the outbreak was declared over on January 11, 2023.
    Background · from our historical context
  6. Uganda declared its 2026 Ebola outbreak over on July 28 after 42 days without detecting further transmission.
    Reported in this story's sourcesSource:zawya.com

How we got here

Ebola is not a single, uniform virus. The name covers several related viruses, and the species responsible for an outbreak matters because immunity or a vaccine candidate designed for one species cannot automatically be assumed to protect against another. The best-known Ebola vaccine products and much of the accumulated clinical evidence concern Zaire ebolavirus.

Bundibugyo ebolavirus and Sudan ebolavirus are distinct species, each associated with separate outbreaks and separate vaccine-development needs. Bundibugyo ebolavirus was identified during an outbreak in western Uganda in 2007.

Original sources

2 of 9 articles · Asia · Show all

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.